A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based Regimen (Bortezomib, Lenalidomide and Dexamethasone) combined with CART-ASCT-CART2 in Chinese patients with newly diagnosed primary plasma cell leukemia.

Trial Details

NCT ID
NCT05870917
Phase
PHASE2
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • anti-BCMA CAR-T
Locations (sample)
  • Tianjin, China|39.14222,117.17667

Key Eligibility Criteria

  • Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that c…
  • Age ≥ 18 years and ≤ 65 years.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.
  • Life expectancy at least 3 months

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →